Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
ConditionT-lymphoblastic Lymphoma
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorZhejiang University
About this trial
A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma
Eligibility criteria
Qualifiers
1. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),
Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments;
Primary drug resistance;
Relapse after autologous hematopoietic stem cell transplantation;
Disqualifiers
1. History of epilepsy or other central nervous system disorders;
2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
3. Active infection of hepatitis B virus, C virus or hepatitis E virus;
4. Active infected persons who are not cured;
Trial design
Treatments tested in this trial
- CD5 CAR T-cells
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Zhejiang University
Lead sponsor
Yake Biotechnology Ltd.
Collaborator
Source ClinicalTrials.gov